HENDERSON, Nev., Oct. 13,
2023 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
has published a report summarising key themes from its recent Key
Opinion Leader ("KOL") roundtable on sepsis management.
Remi Rabeuf, Lifecycle Leader at
Volition, said: "We were delighted to bring together some of the
world's leading experts in sepsis to explore the potential of using
Volition's Nu.Q® NETs technology effectively in clinical practice.
The panel discussed how Nu.Q® NETs could be used to enhance the
management and outcome of sepsis patients and its potential
application in early diagnosis, treatment guidance, treatment
monitoring, and personalized medicine. The KOLs also discussed
areas for future research."
The roundtable was chaired by Professor Djillali Annane, Professor of Medicine at
University Paris Saclay-UVSQ and University Versailles SQY, and
comprised:
- Professor Evangelos J. Giamarellos-Bourboulis, National
and Kapodistrian University of Athens,
Greece and Chair of the European Sepsis Alliance.
- Professor Mervyn Singer, University College London, UK. Co-chair of the Sepsis-3
Definitions International Task Force; past-chair, International
Sepsis Forum; Sepsis Topic Adviser to NICE; Emeritus NIHR Senior
Investigator.
- Professor Adrienne Randolph,
Professor of Anaesthesia and Paediatrics at Harvard Medical School, Paediatric Critical Care
Physician at Boston Children's Hospital, U.S. and Chair of the
International Sepsis Forum.
- Dr Tanya Novak, PhD Scientist at Boston Children's
Hospital and an instructor at Harvard Medical
School, U.S.
- Professor Michael Bauer,
Professor and Chair of the Department of Anaesthesiology and
Intensive Care Medicine at Jena University Hospital, Germany.
- Professor Guillaume Monneret,
Professor of Immunology at Hospices Civils de Lyon, France.
- Professor Lea Payen, Professor in Molecular Biology and
Toxicology at the University of Lyon I and Hospices Civils de
Lyon, France.
- Dr Andrew Aswani, Consultant in Intensive Care Medicine
and Anaesthesia at Guy's and St Thomas' Hospital in London, UK and Co-founder and Chief Medical
Officer of Santersus AG.
- Dr Andrew Retter, Consultant in
Intensive Care Medicine at Guys and St Thomas' Hospital in
London, UK and a Medical
Consultant to Volition.
Read the full KOL Meeting report 'Sepsis: hope of a brighter
future' here.
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's technology go to:
www.volition.com.
About Volition
Volition is a multi-national epigenetics company powered by
Nu.Q®, its proprietary nucleosome quantification platform. Through
its subsidiaries, Volition is developing simple, easy to use, cost
effective blood tests to help diagnose and monitor a range of
life-altering diseases including some cancers and diseases
associated with NETosis such as sepsis and COVID-19. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients but also improve their quality of life. The tests
are based on the science of Nucleosomics™, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
For more information about Volition's Nu.Q® technology go to:
www.volition.com
The contents found at the Volition website address are not
incorporated by reference into this document and should not be
considered part of this document. The website address is included
in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
timing and launch of product sales, and the potential uses,
benefits and effectiveness of its Nucleosomics™ technology
platform, including the Nu.Q® NETs test. Volition's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests, a failure by the marketplace to accept
Volition's, Nu.Q® NETs test or other products based on
its Nucleosomics™ platform; Volition's failure to secure adequate
intellectual property protection; Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; Volition will face fierce competition and
its intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring
markets and their rapid technological change; downturns in domestic
and foreign economies; and other risks, including those identified
in Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Forward-looking statements are based on current
expectations, estimates and projections about Volition's business
based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-publishes-key-opinion-leader-roundtable-report-on-nets-in-sepsis-301956032.html
SOURCE VolitionRx Limited